The American Journal of Managed Care2d
New Therapies Expanding the MASH Treatment Landscape
Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...
Gyre: Intriguing Upcoming Data Catalyst, But I'm Still On Sidelines
Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...
The Pharma Letter3d
FDA approvals fall but small pharma drives innovation, GlobalData finds
Drug approvals by the US Food and Drug Administration fell more than 15% in 2024, but smaller pharmaceutical companies are ...
The American Journal of Managed Care3d
MASH Clinical Trials Historically Underrepresent Certain Groups
Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated ...
The Financial Express3d
FDA drug approvals drop 15.44 percent, but smaller pharma leads innovation: GlobalData
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical contract ...
pharmaphorum6d
EMA panel endorses AI for MASH clinical trials
AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...
The Indian Express6d
EU health regulator clears use of AI tool in fatty liver disease trials
Currently, Madrigal Pharmaceuticals’, Rezdiffra is the only U.S.-approved drug for MASH. Drugmakers such as Novo Nordisk and Eli Lilly are also conducting trials with their blockbuster GLP-1 ...